We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVS icon
51
Novartis
NVS
$292B
$12.4M 0.47%
136,225
– –
XBI icon
52
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$12.3M 0.46%
147,677
– –
ACHC icon
53
Acadia Healthcare
ACHC
$2.85B
$11.6M 0.44%
141,189
– –
RLYB icon
54
Rallybio
RLYB
$84.6M
$11.3M 0.43%
215,883
-1,733
-0.8% -$102K
ALGN icon
55
Align Technology
ALGN
$12.4B
$10.7M 0.4%
50,824
+31,930
+169% +$6.39M
KRTX
56
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$10.5M 0.4%
53,452
+29,836
+126% +$6.4M
LH icon
57
Labcorp
LH
$24.9B
$10.4M 0.39%
51,381
– –
AVTR icon
58
Avantor
AVTR
$9.25B
$9.69M 0.37%
+459,488
New +$9.51M
ITCI
59
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.12M 0.34%
172,371
– –
TVTX icon
60
Travere Therapeutics
TVTX
$5.11B
$8.8M 0.33%
418,520
+170,842
+69% +$3.62M
CVS icon
61
CVS Health
CVS
$134B
$8.72M 0.33%
93,621
-30,182
-24% -$2.91M
OHI icon
62
Omega Healthcare
OHI
$14.7B
$8.56M 0.32%
306,433
– –
ALKS icon
63
Alkermes
ALKS
$8.31B
$8.09M 0.31%
309,613
– –
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.24B
$7.72M 0.29%
672,705
+323,135
+92% +$4.03M
DNLI icon
65
Denali Therapeutics
DNLI
$3.67B
$7.58M 0.29%
272,520
+50,100
+23% +$1.49M
MDRX
66
DELISTED
Veradigm Inc. Common Stock
MDRX
$7.56M 0.29%
428,580
– –
ELV icon
67
Elevance Health
ELV
$83B
$7.51M 0.28%
14,644
– –
HQY icon
68
HealthEquity
HQY
$8.72B
$6.79M 0.26%
110,214
– –
LTC
69
LTC Properties
LTC
$1.99B
$6.48M 0.24%
182,293
– –
A icon
70
Agilent Technologies
A
$39.5B
$6.46M 0.24%
43,191
– –
VECT
71
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$6.35M 0.24%
737,704
-18,798
-2% -$151K
SBRA icon
72
Sabra Healthcare REIT
SBRA
$5.2B
$6.35M 0.24%
510,660
– –
SNY icon
73
Sanofi
SNY
$103B
$5.98M 0.23%
123,454
– –
CTLT
74
DELISTED
CATALENT, INC.
CTLT
$5.67M 0.21%
+125,947
New +$6.85M
CERE
75
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$5.57M 0.21%
176,483
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.